JP2020522266A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522266A5
JP2020522266A5 JP2019566965A JP2019566965A JP2020522266A5 JP 2020522266 A5 JP2020522266 A5 JP 2020522266A5 JP 2019566965 A JP2019566965 A JP 2019566965A JP 2019566965 A JP2019566965 A JP 2019566965A JP 2020522266 A5 JP2020522266 A5 JP 2020522266A5
Authority
JP
Japan
Prior art keywords
seq
nos
region
antibody
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566965A
Other languages
English (en)
Japanese (ja)
Other versions
JP7710827B2 (ja
JP2020522266A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/053997 external-priority patent/WO2018224951A2/en
Publication of JP2020522266A publication Critical patent/JP2020522266A/ja
Publication of JP2020522266A5 publication Critical patent/JP2020522266A5/ja
Application granted granted Critical
Publication of JP7710827B2 publication Critical patent/JP7710827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566965A 2017-06-05 2018-06-04 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質 Active JP7710827B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515316P 2017-06-05 2017-06-05
US62/515,316 2017-06-05
PCT/IB2018/053997 WO2018224951A2 (en) 2017-06-05 2018-06-04 Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations

Publications (3)

Publication Number Publication Date
JP2020522266A JP2020522266A (ja) 2020-07-30
JP2020522266A5 true JP2020522266A5 (enExample) 2021-07-26
JP7710827B2 JP7710827B2 (ja) 2025-07-22

Family

ID=64458754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019566965A Active JP7710827B2 (ja) 2017-06-05 2018-06-04 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質

Country Status (10)

Country Link
US (1) US11149094B2 (enExample)
EP (1) EP3634486A4 (enExample)
JP (1) JP7710827B2 (enExample)
KR (1) KR20200014379A (enExample)
CN (1) CN110785185B (enExample)
AU (1) AU2018281045A1 (enExample)
BR (1) BR112019025583A2 (enExample)
CA (1) CA3065171A1 (enExample)
MX (1) MX2019014576A (enExample)
WO (1) WO2018224951A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
BR112013030352B1 (pt) 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
CN108136012B (zh) * 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
CN108779182A (zh) * 2015-12-28 2018-11-09 麻省理工学院 具有恒定区突变的双特异性抗体及其用途
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
WO2019000105A1 (en) * 2017-06-30 2019-01-03 Zymeworks Inc. STABILIZED CHIMERIC FABES
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient
CN114007646B (zh) * 2019-06-25 2024-05-10 南京金斯瑞生物科技有限公司 抗cd47/抗tigit双特异抗体及其制备方法和应用
WO2021007439A1 (en) * 2019-07-09 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Bispecific antibodies to tnf-alpha and il-1beta and uses thereof
JP2022541249A (ja) * 2019-07-17 2022-09-22 バイオインベント インターナショナル アクティエボラーグ 特定の患者のがんを治療するための抗体の組み合わせ
WO2021041715A2 (en) * 2019-08-30 2021-03-04 University Of Kansas Compositions including igg fc mutations and uses thereof
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
MX2022003149A (es) * 2019-09-27 2022-04-06 Agenus Inc Proteinas heterodimericas.
WO2021143826A1 (zh) * 2020-01-17 2021-07-22 信达生物制药(苏州)有限公司 重组抗程序性死亡受体1和抗分化抗原簇137双特异性抗体制剂及其用途
CA3170416A1 (en) * 2020-02-07 2021-08-12 Quanxuan ZHANG Polypeptide affinity ligands and methods of using
JP7664943B2 (ja) * 2020-03-25 2025-04-18 イーライ リリー アンド カンパニー 多重特異性結合タンパク質およびそれを開発する方法
US11987640B2 (en) * 2020-04-07 2024-05-21 Fred Hutchinson Cancer Center Anti-mesothelin antigen-binding molecules and uses thereof
US11739137B2 (en) * 2020-10-30 2023-08-29 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Single domain antibodies to SARS-CoV-2 nucleocapsid protein
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
US20250026784A1 (en) * 2021-11-29 2025-01-23 Tosoh Corporation Separation method of antibody
CN116178546B (zh) * 2022-10-13 2024-06-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
US12030945B2 (en) 2022-10-25 2024-07-09 Seismic Therapeutic, Inc. Variant IgG Fc polypeptides and uses thereof
WO2024213119A1 (en) * 2023-04-14 2024-10-17 Adaptocue, Llc Ph-sensitive cd47-binding domains and uses thereof
GB202311984D0 (en) * 2023-08-04 2023-09-20 Petmedix Ltd Optimised fc molecules
EP4744681A1 (en) * 2024-08-16 2026-05-20 Shanghai Bao Pharmaceuticals Co., Ltd. COMPLEX TARGETING TARGET CELLS AND ITS USE
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand
US20260109746A1 (en) 2024-10-22 2026-04-23 Gilead Sciences, Inc. Cd4-targeted il-15 molecules and methods of use
WO2026092446A1 (en) * 2024-10-31 2026-05-07 Suzhou Biomissile Pharmaceuticals Co., Ltd. Bispecific antibodies and uses thereoftechnical filed

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN101189028B (zh) * 2004-07-12 2013-05-29 马克罗基因公司 具有变异Fc区的抗体的鉴定和工程化以及使用方法
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
WO2008114011A2 (en) * 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI507525B (zh) * 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
CA2766166A1 (en) * 2009-07-08 2011-01-13 Amgen Inc. Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
TWI654203B (zh) * 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) * 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
CN107287660A (zh) * 2011-09-30 2017-10-24 中外制药株式会社 离子浓度依赖性结合分子文库
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR20210074395A (ko) * 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP3517548A1 (en) * 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
WO2013180200A1 (ja) * 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
JPWO2013180201A1 (ja) * 2012-05-30 2016-01-21 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
PT2970980T (pt) 2013-03-15 2018-11-19 Janssen Biotech Inc Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
JP6456831B2 (ja) * 2013-09-04 2019-01-23 プロテノバ株式会社 イムノグロブリン結合ドメイン多量体
AP2016009222A0 (en) * 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
CN106068274A (zh) * 2014-03-05 2016-11-02 Ucb生物制药私人有限公司 多聚体Fc蛋白
ES2719584T3 (es) * 2014-04-11 2019-07-11 Medimmune Llc Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína
JP2017513481A (ja) * 2014-04-16 2017-06-01 ユーシービー バイオファルマ エスピーアールエル 多量体Ｆｃタンパク質
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CN114773469B (zh) * 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
WO2017011342A1 (en) * 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
AU2016312259B2 (en) * 2015-08-26 2018-12-06 Bison Therapeutics Inc. Multispecific antibody platform and related methods
GB201515745D0 (en) 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins

Similar Documents

Publication Publication Date Title
US12152076B2 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
JP7450535B2 (ja) 単一特異性抗体から多重特異性抗体を生成させるための方法
JP2022544760A5 (enExample)
JP2025094049A (ja) 改善された単鎖可変断片のための材料及び方法
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
RU2018108103A (ru) КОНСТРУКЦИИ, ИМЕЮЩИЕ SIRP-α ДОМЕН ИЛИ ЕГО ВАРИАНТ
EP3641815A1 (en) A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY
US20180371089A1 (en) Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy
AU2024275316A1 (en) Ch3 domain variant or bispecific antibody comprising same
RU2019144115A (ru) Cконструированные мультиспецифические антитела и другие мультимерные белки с асимметричными мутациями в области ch2-ch3
WO2024221187A1 (en) Heteromultimer polypeptides
RU2023105130A (ru) Антителоподобная молекула, включающая гетеродимер на основе белка CD1b (кластер дифференцировки 1) человека
CA3292941A1 (en) Ch3 domain variant or bispecific antibody comprising same
WO2025245176A1 (en) Multispecific antibody constructs
HK40031028A (en) Method for generating multispecific antibodies from monospecific antibodies
HK40031028B (en) Method for generating multispecific antibodies from monospecific antibodies
CN118742566A (zh) 包含用于免疫应答的增强型多特异性结合剂的组合物